ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

1:00PM-2:30PM: Abstract Number: 0776

Follicular Dendritic Cell PD-L1 Expression Promotes Autoreactive Germinal Center Formation

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease I

1:00PM-2:30PM: Abstract Number: 0810

Glucocorticoids in Pregnancy and Lactation: Results of the Systematic Review Informing the EULAR Task Force on Antirheumatic Drugs in Reproduction, Pregnancy and Lactation

Abstracts: Reproductive Issues in Rheumatic Disorders

1:00PM-2:30PM: Abstract Number: 0811

High-Throughput Proteomic Profiling of Longitudinal Serum Samples to Predict Treatment Response in Lupus Nephritis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics

1:00PM-2:30PM: Abstract Number: 0815

Interferon-stimulated Gene Expression in Non-lesional Skin Is Similarly Elevated in Incomplete SLE and SLE

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics

1:00PM-2:30PM: Abstract Number: 0813

Investigating TASL, SLC15A4, & TLR7 Associated Risk SNPs in Systemic Lupus Erythematosus

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics

1:00PM-2:30PM: Abstract Number: 0822

Investigating the Association Between Alcohol Consumption and Spinal Radiographic Progression in Axial Spondyloarthritis: A Longitudinal Cohort Analysis over a Period of 6 Years

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I

1:00PM-2:30PM: Abstract Number: 0788

Long-term Effectiveness of a Lifestyle Intervention for Osteoarthritis: Two-year Follow-up After the “Plants for Joints” Randomized Clinical Trial

Abstracts: Osteoarthritis – Clinical Trials

1:00PM-2:30PM: Abstract Number: 0801

Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Breathe: RA-ILD

1:00PM-2:30PM: Abstract Number: 0791

Optimizing Knee Osteoarthritis Treatment with the Precision Medicine Approach in a Clinical Trial Dataset

Abstracts: Osteoarthritis – Clinical Trials

1:00PM-2:30PM: Abstract Number: 0827

Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme

Abstracts: Vasculitis – ANCA-Associated I

1:00PM-2:30PM: Abstract Number: 0799

Peripheral Biomarker Signatures and a Genetic Risk Score Improve the Identification of RA-ILD Beyond Clinical Risk Factors

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: Breathe: RA-ILD

1:00PM-2:30PM: Abstract Number: 0826

Plasma Exchange for Severe Alveolar Hemorrhage in ANCA-Associated Vasculitis: Emulation of a Target Trial

Abstracts: Vasculitis – ANCA-Associated I

1:00PM-2:30PM: Abstract Number: 0795

Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia

1:00PM-2:30PM: Abstract Number: 0792

Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA

Abstracts: Osteoarthritis – Clinical Trials

1:00PM-2:30PM: Abstract Number: 0814

Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].